From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

Eli Lilly's injectable GLP-1 agonist medicines for obesity and diabetes drove 56% growth in first-quarter sales, but ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, after Norgine's ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

After years of wrangling, OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy agreement that could allow it ...